ClinicalTrials.gg
Not yet recruitingNCT07897266Updated Oct 27, 2026

Non-Invasive Vagus Nerve Stimulation as a Probe to Map Functional Connectivity in Schizophrenia Using Functional Magnetic Resonance Imaging

An interventional study of nVNS (non-invasive vagal nerve stimulation) in Schizophrenia Spectrum Disorders, sponsored by University of Alabama at Birmingham. Not yet recruiting at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Basic science

Updated Oct 27, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
19 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to learn whether a handheld, non-invasive stimulation device called gammaCore Emerald can change brain activity and thinking skills. Researchers will use MRI scans to measure changes in brain activity after stimulation and compare the results among people with schizophrenia, depression, and healthy volunteers.

Read the detailed description

The main aim of this study is to determine whether non-invasive vagal nerve stimulation (nVNS) can modulate large brain networks disrupted in schizophrenia and to understand the timing of connectivity changes caused by stimulation. The central hypothesis that nVNS will (1) reliably activate specific networks in individuals with schizophrenia, (2) partially restore connectivity patterns compared to healthy controls, and (3) produce connectivity changes linked to improvements in cognitive function.

02

Conditions studied

  • Schizophrenia Spectrum Disorders

Browse trials for

Keywords

  • Functional Connectivity in Schizophrenia
03

In context

Schizophrenia

3,563 studies on the registry are indexed under Schizophrenia; 491 are open to participants now.

This study's planned enrollment of 40 is below the median of 71 across 2,944 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,421 studies on the registry; 277 are open to participants now.

Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age19-55 years old, inclusive
  2. Sufficient fluency in English to understand testing procedures and provide
  3. In one of these three diagnostic groups:

    1. Schizophrenia Spectrum Disorder (SSD), which can include the diagnoses of Schizophrenia, Schizoaffective Disorder, Unspecified Schizophrenia Spectrum, Schizophreniform Disorder, Brief Psychotic Episode, or Psychotic Disorder NOS (as defined by and determined by the Mini International Neuropsychiatric Interview (MINI)
    2. Unipolar Major Depressive Disorder (MDD) of any subtype. Depressed participants will have a score of >18 on the Montgomery Asberg Depression Rating Scale (MADRS), as defined by DSM-V and determined by the Mini International Neuropsychiatric Interview (MINI)
    3. Normal healthy controls, individuals with no personal history of any Axis I disorder. Controls will have a MADRS score of \<7.

Exclusion criteria

Exclusion Criteria:

  1. Reported pregnancy and/or nursing. A participant may only take part if they are sexually abstinent or using a reliable method of (birth control pills, Norplant, condoms and spermicide).
  2. Evidence of alcohol or other substance use disorder in the past 3 months
  3. Diagnosis of other primary psychiatric disorder (defined in this case as being the main focus of treatment) as determined by the MINI, such as: bipolar disorder, personality disorders, post-traumatic stress disorder, obsessive-compulsive disorder, dissociative disorders, eating disorder, or cognitive deficits due to neurological conditions
  4. Imminent suicide or homicide risk as determined by the investigator
  5. Being treated with one of the following medications: benzodiazepines or other CNS depressants.
  6. No neurological disease based on medical history (e.g., epilepsy) or significant head injury.
  7. Any of the following disorders are exclusionary: Rheumatoid arthritis; Lupus erythematosus; hepatitis; Autoimmune peripheral neuropathy; Autoimmune pancreatitis; Behcet's disease; Crohn's disease; Autoimmune glomerulonephritis; Grave's disease; Guillain-Barre syndrome; Hashimoto's thyroiditis; Autoimmune polymyositis or polymyalgia; Myasthenia gravis; Narcolepsy; Polyarteritis nodosa; Scleroderma; Sjogren's syndrome; Transverse myelitis; Wegener's granulomatosis; History of seizures (only childhood febrile seizures are allowed)
  8. Patients with prior exposure to VNS therapy whether using an implantable or external device
  9. An active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
  10. A metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
  11. An open wound, rash, infection, swelling, cut, sore, drug patch, or surgical scar(s) on the neck at the treatment location
  12. Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
  13. Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
  14. Exclusion criteria for control subjects include any history of mental illness or psychotropic drug abuse.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    schizophrenia spectrum disorder (SSD)

    will self-administer hand-held nVNS for 4 minutes; fMRI prior to and following

    Device: nVNS (non-invasive vagal nerve stimulation)

Interventions

  • DevicenVNS (non-invasive vagal nerve stimulation)

    hand-held nVNS product for SSD signaling

06

What researchers measure

Primary outcomes

  1. functional Magnetic Resonance Imaging (fMRI)

    Effect on functional connectivity

    Time frame: Within 60 minutes following one-time use of nVNS.

07

Study locations

1 site
08

References and documents

Publications

  • Conway CR, Rush AJ, Aaronson ST, Bunker MT, Gordon C, George MS, Riva-Posse P, Allen RM, Nahas Z, Kriedt CL, Zajecka J, Dunner DL, Quevedo J, Sheline Y, Duffy W, Mickey BJ, Stedman M, Alva G, Manu L, Tran Q, Zorumski CF, Macaluso M, Banov M, Cusin C, Bennett JI, Brown H, Way J, Shy O, Lee YL, McAllister-Williams RH, McIntyre RS, Sackeim HA. Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report. Int J Neuropsychopharmacol. 2026 Jan 6;29(1):pyaf080. doi: 10.1093/ijnp/pyaf080. PubMed 41529263 ↗
  • Conway CR, Aaronson ST, Sackeim HA, George MS, Zajecka J, Bunker MT, Duffy W, Stedman M, Riva-Posse P, Allen RM, Quevedo J, Berger M, Alva G, Malik MA, Dunner DL, Cichowicz I, Banov M, Manu L, Nahas Z, Macaluso M, Mickey BJ, Sheline Y, Kriedt CL, Lee YL, Gordon C, Shy O, Tran Q, Yates L, Rush AJ. Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial. Brain Stimul. 2025 May-Jun;18(3):676-689. doi: 10.1016/j.brs.2024.12.1191. Epub 2024 Dec 18. PubMed 39706521 ↗
  • Aaronson ST, Conway CR, Gordon C, Lee YL, George MS, Zajecka J, Riva-Posse P, Dunner DL, Macaluso M, Rosenquist PB, Mickey BJ, Sheline YI, Hristidis VC, Brown H, Kriedt CL, Tran Q, Bunker MT, Sackeim HA, Rush AJ. Prognostic and Prescriptive Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report. J Clin Psychiatry. 2025 Jul 14;86(3):25m15850. doi: 10.4088/JCP.25m15850. PubMed 40673907 ↗
  • Zhang Z, Zhuo K, Xiang Q, Sun Y, Suckling J, Wang J, Liu D, Sun Y. Dynamic functional connectivity and its anatomical substrate reveal treatment outcome in first-episode drug-naive schizophrenia. Transl Psychiatry. 2021 May 12;11(1):282. doi: 10.1038/s41398-021-01398-4. PubMed 33980821 ↗
  • Lin X, Deng J, Dong G, Li S, Wu P, Sun H, Liu L, Shi J, Fan Y, Lu L, Li P. Effects of Chronic Pharmacological Treatment on Functional Brain Network Connectivity in Patients with Schizophrenia. Psychiatry Res. 2021 Jan;295:113338. doi: 10.1016/j.psychres.2020.113338. Epub 2020 Aug 5. PubMed 32768152 ↗
  • Li X, Liu Q, Chen Z, Li Y, Yang Y, Wang X, Guo X, Luo B, Zhang Y, Shi H, Zhang L, Su X, Shao M, Song M, Guo S, Fan L, Yue W, Li W, Lv L, Yang Y. Abnormalities of Regional Brain Activity in Patients With Schizophrenia: A Longitudinal Resting-State fMRI Study. Schizophr Bull. 2023 Sep 7;49(5):1336-1344. doi: 10.1093/schbul/sbad054. PubMed 37083900 ↗
  • Chopra S, Francey SM, O'Donoghue B, Sabaroedin K, Arnatkeviciute A, Cropley V, Nelson B, Graham J, Baldwin L, Tahtalian S, Yuen HP, Allott K, Alvarez-Jimenez M, Harrigan S, Pantelis C, Wood SJ, McGorry P, Fornito A. Functional Connectivity in Antipsychotic-Treated and Antipsychotic-Naive Patients With First-Episode Psychosis and Low Risk of Self-harm or Aggression: A Secondary Analysis of a Randomized Clinical Trial. JAMA Psychiatry. 2021 Sep 1;78(9):994-1004. doi: 10.1001/jamapsychiatry.2021.1422. PubMed 34160595 ↗
  • Cadena EJ, White DM, Kraguljac NV, Reid MA, Jindal R, Pixley RM, Lahti AC. Cognitive control network dysconnectivity and response to antipsychotic treatment in schizophrenia. Schizophr Res. 2019 Feb;204:262-270. doi: 10.1016/j.schres.2018.07.045. Epub 2018 Aug 8. PubMed 30098853 ↗
  • Han SY, Shim L, Lee HJ, Park MK. Transcutaneous auricular vagus nerve stimulation can modulate fronto-parietal brain networks. Front Neurosci. 2024 Jul 18;18:1368754. doi: 10.3389/fnins.2024.1368754. eCollection 2024. PubMed 39091347 ↗
  • Borgmann D, Rigoux L, Kuzmanovic B, Edwin Thanarajah S, Munte TF, Fenselau H, Tittgemeyer M. Technical Note: Modulation of fMRI brainstem responses by transcutaneous vagus nerve stimulation. Neuroimage. 2021 Dec 1;244:118566. doi: 10.1016/j.neuroimage.2021.118566. Epub 2021 Sep 10. PubMed 34509623 ↗
  • Lewine JD, Paulson K, Bangera N, Simon BJ. Exploration of the Impact of Brief Noninvasive Vagal Nerve Stimulation on EEG and Event-Related Potentials. Neuromodulation. 2019 Jul;22(5):564-572. doi: 10.1111/ner.12864. Epub 2018 Oct 4. PubMed 30288866 ↗
  • Macaluso M, Falola M, White S, Wicken C. An open label pilot study of non-invasive vagal nerve stimulation for treatment resistant major depressive disorder. Poster presented at: American Society of Clinical Psychopharmacology (ASCP) Annual Meeting; May 28-31, 2024; Miami Beach, FL.
  • Sharon O, Fahoum F, Nir Y. Transcutaneous Vagus Nerve Stimulation in Humans Induces Pupil Dilation and Attenuates Alpha Oscillations. J Neurosci. 2021 Jan 13;41(2):320-330. doi: 10.1523/JNEUROSCI.1361-20.2020. Epub 2020 Nov 19. PubMed 33214317 ↗

Individual participant data

Plan to share: No

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07897266
Responsible party
Matthew Macaluso (Bee McWane Reid Endowed Chair in Mood Disorders, Department of Psychiatry & Behavioral Neurobiology, University of Alabama at Birmingham) — Principal investigator
First posted
Oct 27, 2026
Start date
Oct 31, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

Samantha White
Contact
swwhite@uabmc.edu
205-934-9189
Allison Hudson
Contact
abeitzel@uabmc.edu
205-996-7171
Matthew W Macaluso, DO
principal investigator · University of Alabama at Birmingham (UAB)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion